Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q3 2013 · 10-Q
Revenue$419.00K$419.00K+76.1% vs Q3 2012 Net Income-$40.50M-$40.50MN/M vs Q3 2012 EPS Diluted-$0.55-$0.55N/M vs Q3 2012 Operating Income-$40,336,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$21,197,000N/M Margins · derivedOperating margin-9626.7%+3489.2 pt vs Q3 2012
Net margin-9665.4%+3636.3 pt vs Q3 2012
ended Sep 30, 2014 · filed Nov 6, 2014 · 37 d after period end